NovalGen is an immunotherapy company focused on the development of pioneering molecular technologies and cutting-edge biological medicines.
We have set a very ambitious goal - to bring life changing treatments to patients by developing therapeutics that treat cancer and other diseases through our breakthroughs in biological technologies.
OUR LEAD PROGRAMME
Our lead programme is based on activating the T-Cell using a novel receptor targeting system that enables us to target both haematological malignancies and solid tumours.
Our focus, however, spans across a range of medical applications and constitutes differentiated targets
One of the greatest challanges in treating cancers and other diseases is the identification of treatments with the fewest side effects and the most benefit at the greatest economy. This is at the heart of NovalGen's discoveries.
Follow our Journey